Prognostic factors for disease progression in patients with renal cell carcinoma;Análisis de los factores pronósticos de progresión tumoral en el adenocarcinoma renal

Actas Urologicas Espanolas

Volumn 31, Issue 8, 2007, Pages 831-844

  Budia Alba D A ^a   Gomez Perez L ^a   Bango, V ^a   Ruiz Cerda Jl ^a   Sempere, A ^a   Queipo, J A ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Prognostic factors; Progression; Renal tumor

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 35649025744     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(07)73737-3     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer Statistics 2006. Cancer J Clin. 2006; 56(2):106-130.
2. Greenlee R, Murray T, Bolden S, Wingo, P. Cancer statistics. Cancer J Clin. 2000;50(1):7-33.
3. Hellsten S, Johnsen J, Berge T, Linell F. Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur Urol. 1990; 18 Suppl 2:2-3.
4. Di Silverio F, Casale P, Colella D, Andrea L, Seccareccia F, Sciarra A. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer. 2000;88(4): 835-843.
5. Furhman S, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655-663.
6. Crissman H, Steinkamp J. Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations. J Cell Biol. 1973;59(3): 766-771.
7. Vindelov LL, Christensen IJ, Nissen NI. Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standard. Cytometry. 1983;3(5):328-331.
8. Hedley D, Shankey T, Wheeless L. DNA cytometry consensus conference. Cytometry. 1993; 14(5):471-500.
9. Saphiro H. Practical flow cytometry. Extrinsic parameters. third ed. New York: Wiley-Liss; 1995.
10. Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry. 1985;6(4):327-333.
11. Bell E. A classification of renal tumours with observations on the frecuency of the various types. J Urol. 1938:39:238-241.
12. Guilliani L, Gibertf C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long term results and prognostic factors. J Urol. 1990;143(3):468-73; discussion 473-474.
13. Guinan P, Frank W, Saffrin R, Rubenstein M. Staging and survival of patients with renal cell carcinoma. Semin Surg Oncol. 1994:10(1):47-50,
14. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology. 1995;45:34-40; discussion 40-41.
15. Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996; 155(6):1868-1873.
16. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003;30(3):467-480.
17. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. JUrol. 200 1; 166(1):63-67.
18. Delahunt B. Histopathologic prognosis indicators for renal cell carcinoma. Semin Diagn Pathol. 1998; 15(1):68-76.
19. Childs RW. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit Rev Immunol. 2001;21(1-3): 191-203.
20. Campbell S, Russo P, Harried G. Chromophobe cell carcinoma of the kidney: a clinicopathologic study. JUrol. 1996; 155:385A.
21. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995; 154(3):964-967.
22. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604-614.
23. Carter MD, Tha S, McLoughlin MG, Owen DA. Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol. 1992; 147(4):1096-1098.
24. Delahunt B, Nacey JN. Renal cell carcinoma: histological indicators of prognosis. Pathology. 1987; 19(3):258-263.
25. Fujikama K, Sasaki M, Aoyama T, Itoh T. Role of volume weighted mean nuclear volume for predicting disease outcome in patients with renal cell carcinoma. J urol. 1997; 157(4):1237-1241.
26. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76(12):2543-2549.
27. Tsui KH, Shvarts. O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;1638(4): 1090-1095 quiz 1295.
28. Ficarra V, Righetti R, Martignoni G, D'Amico A, Pilloni S, Rubilotta E, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int. 2001;67(2):130-134.
29. Ficarra V, Prayer-Galetti T, Novella G, Bratti E, Maffei N, Dal Bianco M, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol. 2003;43(6):663-669.
30. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763-2771.
31. Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pTI-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer. 2002;94:2590-2595.
32. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina. M, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281-291.
33. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612-624.
34. Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58(4):333-336.
35. Ficarra V, Martignoni G, Maffei N, Brunelli M, Novara G, Zanolla L, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103(1):68-75.
36. Al-Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med. 2003; 127(5):593-596.
37. Goldstein NS. Grading of renal cell carcinoma. Urol Clin North Am. 1999;26:637-642, vii.
38. Medeiros LJ, Jones EC, Aizawa S, Aldape HC, Cheville JC, Goldstein NS, et al. Grading of renal cell carcinoma: Workgroup, No. 2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):990-991.
39. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007;177(2):430-436,
40. Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Githtz BJ, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166(1):54-58.
41. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59(4):532-537.
42. Algaba F, Arce Y, Trias I, Santaularia M, Rosales A. Aplicación de ]as clasificaciones del cáncer renal. Actas urol Esp 2006; 30:372-378.
43. Ruiz-Cerda JL, Hernandez M, Gomis F, Vera CD, Kimler BF, O'Connor JE, et al. Value of deoxyribonucleic acid ploidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma. J Urol. 1996;155(2): 459-465.
44. Grignon DJ, Ayala AG, el-Naggar A, Wishnow KI, Ro JY, Swanson DA, et al. Renal cell carcinoma. A clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer. 1989;64(10):2133-2140.
45. Katusin D, Uzarevic B, Petrovecki M, Mlinac-Lucijanic M, Marusic M, Marekovic Z. Clinical, histopathological and flow-cytometric properties of incidental renal cell carcinomas. Urol Res. 2000;28(1):52-6.
46. Chautard D, Dalifard I, Chassevent A, Guyetant S, Daver A, Vielle B, et al. Prognostic value of uPA, PAI- 1, and DNA content in adult renal cell carcinoma. Urology. 2004;63(6): 1055-1060.
47. Abou-Rebyeh H, Borgmann V, Nagel R, Al-Abadi H. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer. 2001;92(9):2280-2285.
48. Rey D, Pfister C, Gobet F, Martinez S, Staerman F, Grise P. Study of the prognostic value of DNA ploidy and proliferation index (Ki-67) in renal cell carcinoma with venous thrombus. Prog Urol. 2003; 13(6):1300-1306.
49. Ljungberg B, Roos G, Steriling R. Deoxyribonucleic acid content in metastatic renal cell carcinoma: clinical implications. 6Semin Surg Oncol. 1998;4(3):165-168.
50. Shameem 1, Shimabukuro T, Wada T, Kurisu H, Naito K. Expression of proliferation cell nuclear antigen and deoxyribonucleic acid value in renal cell carcinoma: correlation with different histopathological parameters and patient survival. Eur Urol. 1996;29(1):78-84.
51. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Killin R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer. 1996;77(1):164-71.
52. Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis C, et al. Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis? International Journal of Urology. 2005;12(6):563-569.
53. Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, et al. Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Conunittee on Cancer (AJCC). Cancer. 1997;80(5):994-996.
54. Jochum W, Schroder S, al-Taha R, August C, Gross AJ, Berger J, et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 1996; 77:514-21.
55. Papadopoulos, 1, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma.. Eur Urol. 1997;32(1):110-117.
56. Pepe S, Ruggiero A, D'Acquisto M, De laurentiis M, De Placido S, Sandomenico C, et al. Nuclear DNA content- Derived parameters correlated with heterogeneus expression of P53 and bcl-2 proteins in clear cell renal carcinoma. Cancer. 2000;89(5):1065-1075.
57. Banner BF, Ernstoff MS, Bahnson RR, Titus-Ernstoff L, Taylor SR. Quantitative DNA analysis of small renal cortical neoplasms. Hum Pathol. 1991;22(3):247-253.
58. Shalev M, Gdor Y, Leventis A, Radnay J, Shapiro H, Bernheim J, et al. The pronostic value of DNA ploidy in small renal cell carcinoma. Pathol Res Pract. 200 1; 197(1): 7-12.
59. Currin SM, Lee SE, Walther PJ. Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma: does ploidy status enhance prognostic stratification over stage alone?. J Urol. 1990; 143(3):458-463.
60. Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, Leader M. Ploidy and prognosis in renal carcinoma. Br J Urol. 1993;71(1):21-24.
61. Minervini A, Di Cristofano C, Collecchi P, Salinitri G, Selli C, Bevilacqua G, et al. Intracapsular clear cell renal carcinoma: ploidy status improves the prognostic value of the 2002 TNM classification. J Urol. 2005; 174(4 Pt 1): 1203-7; discussion 1207.